Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Lapco

Pompano Beach, FL Medical Doctor

NPI 1174587331 CMS profile 1389056

1 W Sample Rd, Suite 103, Pompano Beach, FL 33064

Open in the dashboard

General payments

$12,529

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$37,523 paid to institutions, not to them · program years 2023–2024

Through program year 2025, Paul Lapco of Pompano Beach, FL is reported in the CMS Open Payments database as having received $12,529 across 228 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $37,523 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,489 37
2024 General $1,387 33
2023 General $2,314 47
2022 General $1,975 32
2021 General $1,840 33
2020 General $1,309 22
2019 General $2,214 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Lapco
  • Florida median
  • Middle half of Florida
  • National median

In program year 2025, general payments to Paul Lapco were reported at $1,489. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.

Show as a table
Year Paul Lapco Florida median Middle half National median
2019 $2,214 $197 $63–$719 $163
2020 $1,309 $126 $38–$436 $114
2021 $1,840 $151 $45–$537 $132
2022 $1,975 $175 $53–$607 $149
2023 $2,314 $183 $57–$637 $160
2024 $1,387 $185 $56–$647 $164
2025 $1,489 $195 $59–$690 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,367 60 payments
  2. Aerin Medical Inc. $2,009 19 payments
  3. Regeneron Healthcare Solutions, Inc. $1,274 41 payments
  4. Genzyme Corporation $1,021 29 payments
  5. Medtronic, Inc. $880 15 payments
  6. Acclarent, Inc $575 13 payments
  7. OptiNose US, Inc. $544 25 payments
  8. Intersect ENT, Inc. $457 9 payments
  9. GlaxoSmithKline, LLC. $105 5 payments
  10. Sanofi-Aventis U.S. LLC $99 1 payment
  11. Other $198 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,758 214 payments
  2. Travel and Lodging $3,615 12 payments
  3. Education $155 2 payments
Products named General payments · program years 2019–2025
  1. XPRESS ENT DILATION SYSTEM $2,346 32 payments
  2. ENTELLUS - XPRESS ENT DILATION SYSTEM $1,983 14 payments
  3. DUPIXENT Immunology $1,487 39 payments
  4. VIVAER STYLUS $1,110 13 payments
  5. DUPIXENT Inflammation And Immunology $731 27 payments
  6. VivAer $679 2 payments
  7. RhinAer $679 2 payments
  8. FIAGON NAVIGATION UNIT $562 4 payments
  9. Xhance $544 25 payments
  10. DUPIXENT Immunology And Inflammation $543 14 payments
  11. Other $2,994 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,555

Median for Otolaryngology: 297

Drug cost

$35,314

Median for Otolaryngology: $6,314

Branded share of claims

2.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xhance Fluticasone Propionate Brand 20 $15,856
Ipratropium Bromide Generic 201 $4,285
Montelukast Sodium Generic 295 $3,075
Azelastine Hcl Generic 107 $2,133
Fluticasone Propionate Generic 162 $1,700
Azelastine-Fluticasone Azelastine/Fluticasone Brand 16 $1,647
Betamethasone Dipropionate Generic 35 $1,213
Mupirocin Generic 166 $1,004
Fluocinolone Acetonide Oil Generic 21 $724
Omeprazole Generic 67 $704

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$235,618

Medicare's payments for the services billed

Medicare patients

412

Average age 76

Services billed

6,579

241 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 58%
Ischemic heart disease 35%
Diabetes 29%
Chronic kidney disease 28%
Depression 27%
Osteoporosis 22%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $335
  • GENZYME CORPORATION $221
$556 — —
Xhance
  • OptiNose US, Inc. $134
$134 20 —
SINUVA
  • Medtronic, Inc. $42
$42 — —
Ryaltris
  • Hikma Pharmaceuticals USA $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record